Goutham Sunny/LinkedIn
Jun 11, 2025, 22:03
Goutham Sunny: New systematic review in EJC 2025 shines a light on a game-changer for LMIC oncology
Goutham Sunny, Former Resident Doctor at The Gujarat Cancer and Research Institute, shared a post on X։
“New systematic review in EJC 2025 shines a light on a game-changer for LMIC oncology! Congratulations Dr Amol Akhadeand
Amol Patelsirs.Low-dose PD-(L)1 inhibitors (e.g., Nivolumab 20–40mg, Pembrolizumab 100mg) show promising efficacy, safety, and ~90% cost savings.
Effective in Hodgkin lymphoma, NSCLC, RCC and MSI-high CRC
ORRs similar to standard-dose pivotal trials
Grade ≥3 irAEs low or absent in many reports
India 🇮🇳 leads with >50% of studies – real-world, pragmatic data
Great potential to combat financial toxicity
Could democratize immunotherapy access in under-resourced settings
Most studies are retrospective with high risk of bias — but several non-inferiority RCTs underway (e.g., DEDICATION-1, REFINE-Lung)
Bottom line:
Low-dose ICI = Hope for equitable cancer care in LMICsLoads of interest in this from India – CMC Vellore has presented data across multiple sites. Let’s push for evidence, equity and access!”
Title: Expanding Access to Cancer Immunotherapy: A Systematic Review of Low-Dose PD-(L)1 Inhibitor Strategies
Authors: Pablo Jiménez-Labaig, Failah Mohamed, Nur Jihan Irwan Tan, Ilves Sanna, Khalid El Bairi, Shah Zeb Khan, Amol Akhade, Teresa Amaral, Dario Trapani, Amol Patel, Kevin J Harrington
Read the Full Article.
More posts featuring Goutham Sunny.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 11, 2025, 21:02